Sökning: WFRF:(Ullenhag Gustav) >
A phase Ib randomiz...
A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)
-
- Bagge, R. Olofsson (författare)
- Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Surg, Gothenburg 41345, Sweden.;Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden.
-
- Nelson, A. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.
-
- Shafazand, A. (författare)
- Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden.;Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden.
-
visa fler...
-
- Cahlin, C. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Transplant Inst, Inst Clin Sci,Sahlgrenska Acad, Gothenburg, Sweden.
-
- Carneiro, A. (författare)
- Skane Univ Hosp, Dept Haematol Oncol & Radiat Phys, Comprehens Canc Ctr, Lund, Sweden.
-
- Helgadottir, H. (författare)
- Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden.
-
- Levin, M. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.
-
- Rizell, M. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Transplant Inst, Inst Clin Sci,Sahlgrenska Acad, Gothenburg, Sweden.
-
- Ullenhag, Gustav (författare)
- Uppsala universitet,Cancerimmunterapi
-
- Wiren, S. (författare)
- Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden.;Umeå Univ Hosp, Dept Radiat Sci, Umeå, Sweden.
-
- Lindner, P. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Transplant Inst, Inst Clin Sci,Sahlgrenska Acad, Gothenburg, Sweden.
-
- Nilsson, J. A. (författare)
- Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden.;Univ Western Australia, Harry Perkins Inst Med Res, Perth, Australia.
-
- Ny, L. (författare)
- Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.
-
visa färre...
-
Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden;Sahlgrens Univ Hosp, Dept Surg, Gothenburg 41345, Sweden.;Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden. Univ Gothenburg, Sahlgrenska Univ Hosp, Inst Clin Sci, Dept Oncol,Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden. (creator_code:org_t)
- Elsevier, 2024
- 2024
- Engelska.
-
Ingår i: ESMO Open. - : Elsevier. - 2059-7029. ; 9:7
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background:Uveal melanoma (UM) is a rare malignancy where 50% of patients develop metastatic disease primarily affecting the liver. Approximately 40% of patients with metastatic UM respond to one-time isolated hepatic perfusion (IHP) with high -dose melphalan. This phase I trial investigates the safety and clinical ef fi cacy of IHP combined with ipilimumab (IPI) and nivolumab (NIVO).Patients and methods:Immunotherapy-na & iuml;ve patients were randomized in this phase I trial to receive either IHP followed by IPI 3 mg/kg and NIVO 1 mg/kg (IPI3/NIVO1) for four cycles (post -operative arm), or one cycle of preoperative IPI3/NIVO1, IHP and then three cycles of IPI3/NIVO1 (pre-post-operative arm), followed by maintenance therapy with NIVO 480 mg for 1 year.Results:Eighteen patients were enrolled and randomized. Three patients did not undergo IHP as planned. In total, 11/ 18 patients (6 in the post -operative arm and 5 in the pre-post-operative arm) did not complete the planned four cycles of IPI3/NIVO1. Toxicity to IHP was similar in both groups, but the number of immune-related adverse events (AEs) was higher in the pre-post-operative arm. Among assessable patients, overall response rate was 57% in the post -operative arm (4/7) and 22% in the pre-post-operative arm (2/9).Conclusions:Combination therapy with IHP and IPI3/NIVO1 was associated with severe AEs. The efficacy of this combination is encouraging with high response rates. One cycle of preoperative IPI/NIVO before IHP did not show potential benefits in terms of safety or efficacy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- isolated hepatic perfusion
- immune checkpoint inhibitor
- PD-1
- CTLA-4
- liver metastases
- uveal melanoma
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bagge, R. Olofss ...
-
Nelson, A.
-
Shafazand, A.
-
Cahlin, C.
-
Carneiro, A.
-
Helgadottir, H.
-
visa fler...
-
Levin, M.
-
Rizell, M.
-
Ullenhag, Gustav
-
Wiren, S.
-
Lindner, P.
-
Nilsson, J. A.
-
Ny, L.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
ESMO Open
- Av lärosätet
-
Uppsala universitet